Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in NAFLD
NCT01963845Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Sitagliptin with Placebo (2 arms). Primary endpoint: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF at 24 weeks. Started Jan 2014; status: completed.
02
Drugs
sitagliptin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01963845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963845.